Several stocks are in focus today as major brokerages have revised their ratings and target prices across key sectors. Financials, auto, metals, and consumer sectors remain in the spotlight.
Key brokerage recommendations:
SBI Cards: HSBC upgrades to Buy, raises target price to ₹1,000, reflecting a positive outlook for the credit card segment.
GPPL: HSBC upgrades to Hold, increases target price to ₹150.
M&M: Goldman Sachs (₹3,800) and Nomura (₹3,681) maintain Buy, citing strong demand in the automobile and EV space.
Reliance Industries: Jefferies maintains Buy, sets a target price of ₹1,660, highlighting its diversified business expansion.
Hindalco: CLSA maintains Outperform, raises target price to ₹815, indicating strength in the metals sector.
IndusInd Bank: CLSA maintains Outperform, with a target price of ₹1,300, signaling steady banking performance.
Bandhan Bank: CLSA maintains Outperform, with a target price of ₹220.
Afcons: Jefferies (₹580) and Investec (₹630) maintain Buy, showing optimism in the infrastructure segment.
Manappuram: CLSA maintains Outperform, with a target price of ₹225.
IGL: Citi maintains Buy, sets a target price of ₹250.
Indus Towers: Citi maintains Buy, with a target price of ₹490.
PI Industries: Citi maintains Buy, raises target price to ₹4,400.
ICICI Bank: Citi maintains Buy, with a target price of ₹1,600.
Jubilant Food: Jefferies (₹1,000) and Morgan Stanley (₹781) maintain Buy, reflecting confidence in QSR segment growth.
Deepak Nitrite: Morgan Stanley maintains Overweight, with a target price of ₹3,000.
Pharma sector: HSBC believes concerns over US tariffs are overdone, expects limited impact on Indian pharma.
Motherson: BofA (₹160), Jefferies (₹165), and JPMorgan (₹160) maintain Buy, despite slight target cuts.
Glenmark: Nomura maintains Neutral, with a target price of ₹1,500.
Concord: Citi maintains Neutral, with a target price of ₹1,880.
Amber Enterprises: Jefferies maintains Buy, with a target price of ₹8,845.
These recommendations indicate positive sentiment across auto, metals, banking, and infrastructure stocks, while select pharma and industrial stocks remain under watch.
Disclaimer: This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research before making any investment decisions.